| |
|
|
|
The Knowledge Foundation, Inc., Cambridge, MA USA
March 8 - 9, 2004
Detailed agenda available at website.
High cholesterol levels remain a leading cause for atherosclerosis and other cardiovascular diseases, despite the multitude of available therapeutics. In order to develop new pharmaceutical approaches for elevating HDL it is essential to gain a greater understanding of the various pathways in HDL -C metabolism and their regulation.
In it’s 5th year, this conference provides cutting-edge data on cholesterol efflux, transfer proteins, scavenger receptors, nuclear receptors, hepatic lipase, ABCA1 and apolipoprotein A. Top experts from industry and academia present powerful strategies for reducing the risk of cardiovascular diseases by improving the atherosclerotic protection. Discover the latest developments in such topics as: • The role of ceramide in the modulation of ABCA1-mediated cholesterol efflux
• Understanding the regulation of HDL-C by using natural genetic variation as a tool
• Analysis of SR-BI
• RXR agonists as regulators for dietary cholesterol
• Paraoxonase1 and it’s anti-atherosclerotic properties
• LXR in lipid metabolism
• HDL-raising drugs
• Hepatic Lipase modulates lipoprotein metabolism
• Molecular dynamics of ApoA-I
• ABCA1 / apolipoprotein interactions Register early to hear the latest on HDL Cholesterol and it’s metabolic pathways! Pre-Conference Seminar: Metabolic Syndrome: Current Challenges and Future Trends Monday,
March 8, 2004 This seminar will present the opportunity to discuss the newest insights in metabolic syndrome with the experts. Strategies on lipid lowering therapies will be given, the effects of fibrates on metabolism of statins will be
discussed, as well as the effect of ACC inhibitors.
|
|
|
|
|
|
|
|
Organized by:
|
|
The Knowledge Foundation, Inc. |
|
|
Invited Speakers:
|
|
M. Krieger, MIT
J. Thompson, Pfizer
J. Oram, U. Washington
D. Black, Merck
M. Pfahl, MaxoCore Pharmaceuticals, Inc.
C. Rittershaus, Avant
S. Davidson, U. Cincinnati
A. Remaley, NIH
N. Miller, London, UK
S. Santamarina-Fojo, NIH
J. Ordovas, Tufts
B. Wagner, X-Ceptor
K. Feingold, UCSF
G. Coppola, Novartis
T. Forte, Lawrence Berkley National Lab
M. Oda, U. Oakland
G. Cao, Lilly
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
for poster presentation: March 5 (info at website)
|
|
|
|
|
|
|
|
Registration:
|
|
via phone: 617-232 7400
online registration available.
|
|
|
E-mail:
|
|
meder@knowledgefoundation.com
|
|
|
|
|
|
|
|
|